Daxor Expands Blood Volume Analysis Technology in New Hospitals

Daxor Corp (DXR) has expanded its blood volume analysis technology to three additional hospitals, driven by its CLIA-certified ezBVA Lab service and on-site analyzer. The company expects continued robust sales growth through 2025, with notable recent expansions including a major healthcare center in Tennessee and a prominent referral hospital covering Arizona, Nevada, and Utah. Analysts forecast an average target price of $25.00, implying an upside of 172.23% from the current price of $9.18.

Daxor Corporation (DXR) has announced the expansion of its blood volume analysis (BVA) technology into three new hospitals, a testament to the growing recognition of BVA's essential role in improving lives and reducing healthcare costs. The company's CLIA-certified ezBVA Lab service, which delivers on-demand, next-day blood volume analysis results, and on-site placement of its blood volume analyzer have driven this growth. The recent expansions include a major healthcare center in Tennessee and a prominent referral hospital covering Arizona, Nevada, and Utah.

Michael Feldschuh, Daxor Corporation CEO and President, stated, "We are incredibly proud to announce the expansion of our BVA technology into three renowned facilities as a testament to the growing recognition of BVA's pivotal role in improving lives and reducing healthcare costs. This momentum, driven by the increasing integration of our ezBVA Lab Service and on-site analyzers, underscores our commitment to providing clinicians, regardless of location, with precise tools to guide optimal fluid management."

Daxor's BVA-100® (Blood Volume Analyzer) is the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care.

The company expects accelerated sales growth to continue throughout 2025 as clinicians increasingly embrace the benefits of BVA for optimizing fluid management decisions. Analysts forecast an average target price of $25.00, implying an upside of 172.23% from the current price of $9.18.

References:
[1] https://daxor.com/daxors-blood-volume-analysis-technology-accelerates-market-penetration-with-three-new-facility-adoptions/
[2] https://www.globenewswire.com/news-release/2025/07/22/3119371/0/en/Daxor-s-Blood-Volume-Analysis-Technology-Accelerates-Market-Penetration-with-Three-New-Facility-Adoptions.html